ADMA
ADMA Biologics, Inc.
NASDAQ · USHealthcareBiotechnology
$8.75+0.46%
Price as of Jul 20, 2026
ADMA profitability
ADMA Biologics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 61.3%
- EBITDA margin
- 43.4%
- EBIT margin
- 40.6%
- Net margin
- 32.4%
- Free cash flow margin
- 21.2%
Returns
- Return on equity
- 42.4%
- Return on assets
- 24.9%
- Return on invested capital
- 34.8%
- Asset turnover
- 0.79x
Cash efficiency
- Cash from operations
- $128.3M
- Cash per share
- $0.60
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.